Yajing Xu

ORCID: 0000-0001-9228-6648
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • T-cell and B-cell Immunology
  • Chronic Lymphocytic Leukemia Research
  • Histone Deacetylase Inhibitors Research
  • Epigenetics and DNA Methylation
  • RNA Interference and Gene Delivery
  • Cancer Immunotherapy and Biomarkers
  • MicroRNA in disease regulation
  • DNA Repair Mechanisms
  • Kruppel-like factors research
  • Polyomavirus and related diseases
  • Advanced biosensing and bioanalysis techniques
  • Immune Cell Function and Interaction
  • Platelet Disorders and Treatments
  • Chronic Myeloid Leukemia Treatments
  • DNA and Nucleic Acid Chemistry
  • Stochastic processes and financial applications
  • Immune responses and vaccinations
  • Cystic Fibrosis Research Advances
  • Complement system in diseases
  • Bladder and Urothelial Cancer Treatments
  • Biological Activity of Diterpenoids and Biflavonoids
  • Multiple Myeloma Research and Treatments

Central South University
2013-2025

Xiangya Hospital Central South University
2013-2025

Zhengzhou University of Light Industry
2011-2022

Changzhou No.2 People's Hospital
2020-2021

Nanjing Medical University
2020-2021

Wenzhou Medical University
2021

First Affiliated Hospital of Wenzhou Medical University
2021

The University of Texas Health Science Center at San Antonio
2020

City Of Hope National Medical Center
2014

The optimal dose of rabbit antithymocyte globulin (ATG, ImtixSangstat) minimizing infections without increasing graft-versus-host disease (GVHD) is unknown in T cell-replete, G-CSF-primed haploidentical hematopoietic stem cell transplantation (haplo-HSCT).Four hundred and eight patients were enrolled this multicenter study to evaluate the effect 7.5 mg/kg 10.0 ATG on viral GVHD prophylaxis after haplo-HSCT. primary endpoint was EBV DNAemia within 1 year posttransplantation.The 1-year...

10.1186/s12916-019-1393-7 article EN cc-by BMC Medicine 2019-08-12

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease and remains clinically challenging. Currently chemotherapies are frequently associated with treatment-related death long-term side effects. Therefore, alternative approaches lower toxicity highly desired. Ginsenosides metabolites the main ingredients responsible for multiple pharmaceutical functions of ginseng, which one most commonly consumed herbal medicines world widely. In present study, we demonstrated that compound K,...

10.1186/1475-2867-13-24 article EN cc-by Cancer Cell International 2013-01-01

Atherosclerosis (AS) is the main pathological basis of cardiovascular diseases, which are related to high morbidity and mortality rates. The present study aimed investigate role Krüppel‑like factor 5 (KLF5)/LINC00346/miR‑148a‑3p loop in AS. expression levels KLF5 serum KLF5/LINC00346/miR‑148a‑3p human umbilical vein endothelial cells (HUVECs) were detected by RT‑qPCR analysis. protein KLF5, phosphorylated (p‑)endothelial nitric oxide synthase (eNOS) eNOS HUVECs analyzed western blot Changes...

10.3892/ijmm.2021.4985 article EN International Journal of Molecular Medicine 2021-06-17

Chronic graft-versus-host disease (cGVHD) is an autoimmune-like syndrome, and donor B cells play important roles in augmenting its pathogenesis. cell–depleting anti-CD20 mAb has been administered before or after cGVHD onset for preventing treating the clinic. Although administration appeared to be more effective, effect variable sometimes minimal. Here, we used 2 mouse models evaluate preventive therapeutic of mAb. With model DBA/2 MHC-matched BALB/c recipient, 1 intravenous injection (40...

10.1016/j.bbmt.2014.04.028 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2014-05-04

Objective: To develop predictive models for contrast induced acute kidney injury (CI-AKI) among myocardial infarction (AMI) patients treated invasively. Methods: Patients with AMI who underwent angiography therapy were enrolled and randomly divided into training cohort (75%) validation (25%). Machine learning algorithms used to construct CI-AKI. The tested in a cohort. Results: A total of 1,495 included. Of all the patients, 226 (15.1%) cases developed In cohort, Random Forest (RF) model top...

10.3389/fmed.2020.592007 article EN cc-by Frontiers in Medicine 2020-11-13

Background:The expression patterns and prognostic significance of the Rho family GTPases in acute myeloid leukemia have not been systematically studied yet.Methods: In our study, we analyzed 21 gene members AML patients based on GEPIA database.10 with significant differential tissue healthy were selected for subsequent research.Survival curve analysis TCGA GEO dataset preliminary showed that RhoBTB3 is related prognosis non-M3 patients.The bone marrow normal was verified by RT-qPCR.We...

10.7150/jca.50472 article EN cc-by-nc Journal of Cancer 2021-01-01

Background: Immunotherapy has recently shown remarkable efficacy for advanced bladder cancer patients. Accordingly, identifying a biomarker associated with the programmed cell death protein 1 (PD-1)/its ligand (PD-L1) genomic signature to predict patient prognosis is necessary. Methods: In this study, we used mutation data and RNA-seq of samples acquired from The Cancer Genome Atlas (TCGA) database combine PD-1/PD-L1-associated mutational signatures differentially expressed genes (DEGs)....

10.3389/fgene.2021.736158 article EN cc-by Frontiers in Genetics 2021-12-16

To explored the diagnosis and treatment of chronic neutrophilic leukemia (CNL) complicated with multiple myeloma (MM).The clinical features molecular biological characteristics 2 patients CNL MM were summarized, retrospectively reviewed.The was established in cases. Case 1 had CSF3R mutation (P733T), but CSF3R-exon 14 SETBP1 all negative. The neutrophil count returned to normal when successfully treated case 1. When patient relapsed, increased again.Coexistence is rare. a very important...

10.3760/cma.j.issn.0253-2727.2016.08.011 article EN PubMed 2016-08-14

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) maintains the only promising curative option for patients with refractory/relapsed (R/R) acute myeloid leukemia (AML). However, long-term survival results are suboptimal. Optimization of conditioning regimen aims to eradicate blasts and reduce early relapse. Here we reported preliminary result prospective multicenter single arm study evaluate efficacy safety a modified dual alkylator-conditioning regimen, MCBC (regimen including...

10.62347/skxb3242 article EN American Journal of Cancer Research 2024-01-01

To compare the efficacy and safety of gecacitinib (also known as jaktinib) with hydroxyurea (HU) in treating myelofibrosis (MF) patients. In this multicenter, randomized phase 3 trial (ZGJAK016), intermediate- or high-risk primarily JAK inhibitor naïve MF patients were assigned a 2:1 ratio to receive either (100 mg twice day, BID) HU (500 BID). The primary endpoint was proportion ≥35% reduction spleen volume (SVR35) from baseline at week 24. Secondary endpoints included best response rate,...

10.1038/s41408-024-01202-8 article EN cc-by-nc-nd Blood Cancer Journal 2024-12-18

STAT3 is highly expressed in aGVHD CD4 + T cells and plays a critical role inducing or worsening aGVHD. In our preceding studies, DNA hypomethylation promoter was shown to cause high expression of cells, the process could be modulated by HMGB1, but underlying mechanism remains unclear. TET2, AID, TDG are indispensable demethylation; meanwhile, TET2 AID also serve extremely important roles immune response. So, we speculated these enzymes involved induced HMGB1 cells. this study, found that...

10.1155/2020/7165230 article EN cc-by Journal of Immunology Research 2020-09-24

Topic: 16. Myeloproliferative neoplasms - Clinical Background: HMPL-306 is a potent selective inhibitor of mutant IDH1/2. Aims: The phase 1 study aimed to evaluate safety, tolerability, recommended 2 (RP2D), pharmacokinetics/pharmacodynamics (PK/PD) and preliminary efficacy in patients (pts) with relapsed/ refractory myeloid hematological malignancies (HMs) carrying IDH1 2. Methods: open-label, multicenter included dose escalation expansion phases. Pts relapsed/refractory HMs and/or were...

10.1097/01.hs9.0000969064.86312.d3 article EN cc-by-nc-nd HemaSphere 2023-08-01

To screen aptamers binding CD33+/CD34- cells from patients with acute myeloblastic leukemia M2 subtype (AML-M2).CD33+/CD34- AML-M2 were taken as targeted cells, CD33+/ CD34- normal people anti-selecting and in the single strand deoxyribonucleic acid (ssDNA) library then selected repeatedly by cell-systematic evolution of ligands exponential enrichment (C-SELEX) technology, amplified polymerase chain reaction (PCR) to generate sub-ssDNA library. During experiment, PCR amplification...

10.3969/j.issn.1672-7347.2012.08.003 article EN PubMed 2012-08-01

In view of the fact that different factor Copula models are only applicable to practical problems in collateralized debt obligations (CDO) market and there is no semianalytical solution under nonhomogeneous assumptions CDO pricing model, we designed a general numerical algorithm which was based on framework single model randomized quasi-Monte Carlo (RQMC) simulation method. We took two as examples conduct empirical study, results RQMC Monte (MC) method were compared analyzed variance...

10.1155/2022/3802445 article EN Mathematical Problems in Engineering 2022-04-23
Coming Soon ...